These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34727356)

  • 21. Healthcare costs of urinary tract infections and genital mycotic infections among patients with type 2 diabetes mellitus initiated on canagliflozin: a retrospective cohort study.
    Amos TB; Montejano L; Juneau P; Bolge SC
    J Med Econ; 2017 Mar; 20(3):303-313. PubMed ID: 27826987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fracture risk and healthcare resource utilization and costs among osteoporosis patients with type 2 diabetes mellitus and without diabetes mellitus in Japan: retrospective analysis of a hospital claims database.
    Sato M; Ye W; Sugihara T; Isaka Y
    BMC Musculoskelet Disord; 2016 Nov; 17(1):489. PubMed ID: 27887655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diabetes-Related Complications and Costs in Medicare Beneficiaries with Comorbid Rheumatoid Arthritis and Diabetes Treated with Abatacept Versus Other Targeted DMARDs.
    Patel V; Pulungan Z; Shah A; Jones B; Petrilla A; Ferri L; Han X; Michaud K
    Rheumatol Ther; 2022 Aug; 9(4):1091-1107. PubMed ID: 35604547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Retrospective Cohort Study of Patients with Type 2 Diabetes in China: Associations of Hypoglycemia with Health Care Resource Utilization and Associated Costs.
    Yi Y; Li Y; Hou A; Ge Y; Xu Y; Xiong G; Yang X; Acevedo SA; Shi L; Xu H
    Diabetes Ther; 2018 Jun; 9(3):1073-1082. PubMed ID: 29623592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Early Initiation of Eslicarbazepine Acetate on Economic Outcomes Among Patients with Focal Seizure: Results from Retrospective Database Analyses.
    Mehta D; Davis M; Epstein AJ; Wensel B; Grinnell T; Williams GR
    Neurol Ther; 2020 Dec; 9(2):585-598. PubMed ID: 32949379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence of corneal adverse events in patients with multiple myeloma and their clinical and economic impact: A real-world retrospective cohort study.
    Wang F; Sansbury L; Ferrante S; Maiese EM; Willson J; Chen CC; Nunna S; Sun K; Kleinman DM
    J Med Econ; 2022; 25(1):182-192. PubMed ID: 35023807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
    Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
    J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost of cardiovascular diseases and renal complications in people with type 2 diabetes mellitus in the Kingdom of Saudi Arabia: A retrospective analysis of claims database.
    Al-Jedai AH; Almudaiheem HY; Alissa DA; Al-Enazy HS; Korayem GB; Alghamdi A; Alghamdi S
    PLoS One; 2022; 17(10):e0273836. PubMed ID: 36264903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cost of cardiovascular-disease-related death in patients with type 2 diabetes mellitus.
    Shetty S; Stafkey-Mailey D; Yue B; Coutinho AD; Wang W; Del Parigi A; Sander SD; Coleman CI
    Curr Med Res Opin; 2018 Jun; 34(6):1081-1087. PubMed ID: 29480076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia.
    Vekeman F; Sasane M; Cheng WY; Ramanakumar AV; Fortier J; Qiu Y; Duh MS; Paley C; Adams-Graves P
    J Med Econ; 2016; 19(3):292-303. PubMed ID: 26618853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece.
    Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsimihodimos V; Diogo V; Karpouzos G; Papageorgiou G; Kourlaba G
    Clin Drug Investig; 2021 Apr; 41(4):371-380. PubMed ID: 33687695
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
    Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
    Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.
    Bergeson JG; Worley K; Louder A; Ward M; Graham J
    J Manag Care Pharm; 2013 Jun; 19(5):374-84. PubMed ID: 23697475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis.
    Wu B; Deshpande G; Gu T; Popelar B; Philbin M; Wan GJ
    J Med Econ; 2017 Nov; 20(11):1170-1177. PubMed ID: 28760047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Healthcare Resource Utilization and Costs between Rivaroxaban and Warfarin for Nonvalvular Atrial Fibrillation in a Skilled Nursing Facility Setting.
    Mahajan D; Wu B; Song J; Milentijevic D; Ashton V; Mittal VS
    Drugs Aging; 2020 Apr; 37(4):281-289. PubMed ID: 32147804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular-related healthcare resource utilization and costs in patients with hypertension switching from metoprolol to nebivolol.
    Chen S; Fu AC; Jain R; Tan H
    Am Health Drug Benefits; 2015 Apr; 8(2):71-80. PubMed ID: 26005514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.
    Hao Y; Li N; Fang AP; Koo V; Peeples M; Kageleiry A; Wu EQ; Guérin A
    Adv Ther; 2016 Jun; 33(6):983-97. PubMed ID: 27216253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States.
    Tepper SJ; Fang J; Zhou L; Shen Y; Vo P; Abdrabboh A; Glassberg MB; Ferraris M
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1157-1170. PubMed ID: 33998825
    [No Abstract]   [Full Text] [Related]  

  • 39. Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting.
    Lin J; Trocio J; Gupta K; Mardekian J; Lingohr-Smith M; Menges B; You M; Nadkarni A
    J Med Econ; 2017 Sep; 20(9):952-961. PubMed ID: 28604139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
    Reifsnider OS; Kansal AR; Gandhi PK; Cragin L; Brand SB; Pfarr E; Fahrbach K; Ustyugova A
    BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.